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Lycopene was reported to influence some cytochrome P450 enzymes activity. The present study 
investigates the effect of lycopene on the pharmacokinetics of paracetamol and chlorzoxazone. Lycopene 
(20 mg/kg) was intra-peritoneally administered to two groups of rats for eight consecutive days and two 
other groups were given vehicle. On the eighth day, chlorzoxazone and paracetamol were separately 
intravenously administered to a lycopene group and a control group. Blood samples were collected at 
different time intervals, treated and analyzed using HPLC. The HPLC method used for paracetamol 
analysis was based on isocratic elution using a mobile phase consisting of water: methanol, (77:23 v/v) 
at a flow rate 1 mL min−1, Kromasil C18 column, and UV detection at 254 nm using caffeine as internal 
standard. About chlorzoxazone, separation was carried out using water: acetonitrile (60: 40, v/v) as 
the mobile phase at a flow rate 1 mL min−1, Inertsil ODS-3 C18 column, UV detection at 283 nm and 
esomeprazole as internal standard. Statistical analysis of the pharmacokinetic data using student t test 
showed a significant increase in AUC0–t, AUC0-Inf and t1/2 of paracetamol (P<0.05) and of chlorzoxazone 
(P<0.05) in the groups pretreated with lycopene (20 mg/kg), significant increase in the volume of 
distribution of paracetamol (P < 0.05), but no significant difference in that of chlorzoxazone. In other 
words, paracetamol and chlorzoxazone showed significant decrease (P < 0.05), respectively. These results 
demonstrate that treatment of rats with Lycopene (20mg/kg, ip) has a significant effect on the metabolic 
clearance and the pharmacokinetics of both drugs.
Keywords: Lycopene/ chemistry. Paracetamol/pharmacokinetics. Chlorzoxazone/pharmacokinetics. 
Acetaminophen/pharmacokinetics. AUC. Area under curve. Volume of distribution. Validation studies. 
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Rats/metabolism.
INTRODUCTION
Lycopene is a non provitamin A carotenoid, 
concentrated in tomatoes and other red fruits (Schulzová, 
Hajšlová, 2007). Great interest to lycopene was recently 
observed because most studies proved that those who 
consume more lycopene and accordingly have high 
concentrations in plasma have lower incidence for chronic 
illness such as cancer and coronary heart diseases (Gerster, 
1997; Rao, Agarwal, 1999). More studies proved the effect 
of lycopene to decrease bone resorption and thus improve 
osteoporosis (MacKinnon et al., 2011).
In a previous study, Tomato juice showed a potent 
inhibitory effect on nifedipine oxidation activity, which 
was comparable to that on testosterone 6β-hydroxylation 
activity, and weak inhibitory effect on midazolam 
1′-hydroxylation activity ,by one or more mechanism-
based and competitive inhibitor(s) of CYP3A4 (Sunaga 
et al., 2012). 
Hence, the carotenoid lycopene is increasingly 
gaining scientific attention because of its potential health 
effects. However, little is known about the metabolic 
interactions between lycopene and clinically used drugs 
like paracetamol and chlorzoxazone. 
Paracetamol (acetaminophen,  N-acetyl-p-
aminophenol, PAR) is one of the most popular and widely 
used drugs for the treatment of pain and fever. Due to 
its good tolerability profile, PAR is often the analgesic 
or antipyretic of choice, especially in patients in whom 
salicylates or other non-steroidal anti-inflammatory drugs 
are contraindicated (Portolés et al., 2003; Wang et al., 2018).
Cytochrome P450 enzymes, CYP2E1 and CYP1A2, 
catalyze oxidation of PAR to the reactive metabolite iD
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N-acetyl-p-benzoquinone imine (NAPQI) (McGill, 
Jaeschke, 2013). Numerous drugs have been reported to 
interact with PAR leading to exacerbation of its toxicity, 
so PAR should be administered carefully to people on 
isoniazid treatment or consuming excessive amounts of 
alcohol to prevent hepatotoxicity due to the induction 
of CYP2E1. PAR toxicity can occur when CYP2E1 
metabolism is impaired by drug-drug interactions (Zand 
et al., 1993).
Chlorzoxazone (5-chloro-2(3H)-benzoxazolone; 
CZX), a skeletal muscle relaxant used for the treatment 
of painful muscle spasms is primarily metabolized 
to 6-hydroxychlorzoxazone (OH-CZX), which is 
subsequently glucuronidated and excreted in the urine 
(Kar, 2005; Kramer et al., 2003). Hepatic microsomal 
cytochrome P450 enzyme (CYP2E1) plays an important 
role in the formation of OH-CZX from CZX in humans 
and rats (Rockich, Blouin, 1999; Peter et al., 1990). 
Previous studies showed that lycopene has the ability to 
inhibit CYP2E1 in the rat microsomal model (Louisa et 
al., 2009). So far, there has been no information about the 
effects of Lycopene on the pharmacokinetics of CZX and 
PAR. The aim of this study was to determine this influence 
in rats using bioanalytical HPLC method.
MATERIAL AND METHODS
Chemicals and solvents
Lycopene extract was kindly supplied from UG 
PHARMA company, Badr City, Egypt. Paracetamol, 
chlorzoxazone, esomeprazole and caffeine were kindly 
supplied from Memphis Company, Cairo, Egypt. Heparin 
(Calheparin 5000UI AMP) was purchased from Amoun 
Pharmaceutical Industries Company, Kaliobeya, Egypt). 
Methanol for HPLC and ethyl acetate were purchased from 
Sigma-Aldrich, Munich, Germany. Bi‐distilled water was 
produced in‐house (Aquatron Water Still, A4000D, UK).
Instrumentation
 
A chromatographic system (Younglin instrument 
Acme 9000, Korea) equipped with vacuum degasser, 
mixer, gradient pump and UV/VIS detector was used. 
Separation and quantitation were made on Kromasil® 
C18 column (150 x 4.6 mm, 5μm), Agilent, USA and 
Inertsil ODS-3:C18 column (250 x 4.6 mm, 5μm), 
Japan. Magnetic stirrer model Labinco L33, Fronteir TM 
Centrifuge FC5706, OHAUS, Germany and Ultrasonic 
processor; Soniclean 120T, Barton SA, Australia were 
used.
Lycopene stock solution
Lycopene extract 10% equivalent to 200 mg was 
dissolved in 10 mL water to obtain a final concentration 
20 mg/mL of pure lycopene.
Animal experiment
24 Male Wister rats, 250–450 g, obtained from the 
Laboratory Animal Center, Faculty of Pharmacy, Cairo 
University, were housed, six rats per cage, and given free 
access to food and water in a temperature-controlled room 
(25˚C) with a 12 h light/dark cycle. The study protocol 
was reviewed and approved (PC (1687) on 26th April 
2016 by the Institutional Review Board (REC-FOPCU; 
Research Ethics Committee-Faculty of Pharmacy, Cairo 
University) in Egypt. All applicable international, national, 
and/or institutional guidelines for the care and use of 
animals were followed. The rats were randomLy divided 
into four groups: (1) Lycopene group of PAR (pretreated 
with lycopene (20 mg/kg, n=6) (2) Control group of 
PAR (pretreated with vehicle (water for injection), n=6) 
(3) Lycopene group of CZX (pretreated with lycopene 
(20 mg/kg), n=6) (4) Control group of CZX pretreated 
with vehicle (normal saline), n=6). 
All the rats were given vehicle (control group) or 
lycopene (lycopene group) intraperitoneally on a daily 
basis for 8 consecutive days. On the eighth day, access 
to the diet was removed and only water was provided. 
After treatment with water or lycopene, PAR (25 mg/kg) 
was given to group (1) and group (2) and CZX (20 mg/kg) 
was given to group (3) and group (4) by intravenous 
administration in the tail. 
After administration of PAR and CZX, 300 µL blood 
samples were collected from the vein of the eye at different 
time intervals (0, 0.25, 0.5, 1, 2, 4, 6 hr). The plasma 
samples were separated via Eppendorf containing 50µL 
of diluted heparin (1:10) by centrifugation at 4,000 rpm 
for 15 min and stored at -20oC until analysis.
Extraction method of PAR
A liquid-liquid extraction method was used for 
extraction of PAR from plasma matrix. In an Eppendorf, an 
aliquot of 20 µL internal standard stock solution (Caffeine 
400µg/mL) and 60 µL water were added to 120 µL plasma 
samples taken from groups (1) and (2) and then 1000 µL of 
a mixture of methanol and ethyl acetate (1:9) was added. 
The solution was vortexed for 30 s and the supernatant was 
separated by centrifugation at 4,000 rpm for 10 min. The 
organic layer was separated and evaporated to dryness at 
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40 °C under a gentle stream of nitrogen. The residue was 
reconstituted in 100 µL mixture of methanol and water 
(77: 23), then 20 µL was injected onto HPLC. The final 
concentration of IS is 80µg/mL.
Extraction method of CZX
A protein precipitation method was used for 
extraction of CZX from plasma matrix. An aliquot of 
20 µL internal standard stock solution (Esomeprazole, 
880µg/mL) and 60 µL water were added to 120 µL plasma 
samples taken from groups (3) and (4) in Eppendorf and 
then 200 µL of a mixture of water and acetonitrile (4:6) 
was added. The solution was vortexed for 30 s and the 
supernatant was separated by centrifugation at 6,000 rpm 
for 15 min, then 20 µL was injected onto HPLC. The final 
concentration of IS is 44µg/mL.
Assay of PAR in rat plasma
PAR plasma concentration was determined using 
HPLC. Chromatographic separation was achieved on 
a Kromasil C18 column (150 X 4.6 mm, 5μm) using a 
mobile phase consisting of water: methanol (77:23, v/v) 
at a flow rate 1 mL min−1. The column temperature was 
25 °C. UV detector was operated at 254 nm. The injection 
volume was 20 µL.
Assay of CZX in rat plasma
Chromatographic separation of CZX plasma 
concentration was achieved on an Inertsil C18 column 
(250 X 4.6 mm, 5μm) using a mobile phase consisting of 
water: acetonitrile (60:40, v/v) at a flow rate 1 mL min−1. 
The column temperature was 25 °C. UV detector was 
operated at 283 nm. The injection volume was 20 µL.
Bioanalytical method validation (EMA, 2015)
Preparation of Calibration standards and quality control 
samples
Stock solutions of PAR (2.5-200 µg mL-1) were 
diluted in water to get concentrations of calibration 
curve (0.5-40 µg mL-1). Stock solutions of PAR (2.5, 
7.5, 100, 150 µg mL-1) were diluted in water to get 
quality control samples (LLOQ = 0.5, Low = 1.5, 
Med =20, High = 30 µg mL-1). Stock solution of caffeine 
(400 µg mL-1) was diluted in distilled water to get 
concentration (80 µg mL-1) (IS). A 100 µL aliquot of rat 
plasma was spiked with 20 µL of stock solution, 20 µL of 
Caffeine stock solution (IS) and 60 µL water. To 200 μL 
of the spiked calibration plasma standards or QC samples, 
1000 µL mixture of ethyl acetate and methanol (9:1) was 
added and the extraction procedure was continued as 
mentioned in “Extraction method of PAR”. 
Stock solutions of CZX (10-800 µg mL-1) were 
diluted in acetonitrile to get concentrations of calibration 
curve (0.5-40 µg mL-1). Stock solutions of CZX (10, 30, 
400, 600 µg mL-1) were diluted in acetonitrile to get quality 
control samples (LLOQ = 0.5, Low = 1.5, Med = 20, 
High=30 µg mL-1). Stock solution of Esomeprazole 
(880 µg mL-1) was diluted in distilled water to get 
concentration (44 µg mL-1) (IS). A 100 µL aliquot of rat’s 
plasma was spiked with 20 µL of stock solution, 20 µL 
of Esomeprazole stock solution (IS) and 60 µL water. To 
200 μL of the spiked calibration plasma standards or QC 
samples, 200µL mixture of acetonitrile and water (6:4) 
was added and the extraction procedure was continued as 
mentioned in “Extraction method of CZX”.
Calibration curves were constructed by plotting peak 
area ratio of the drug to IS versus the corresponding drug 
concentration in both PAR and CZX. The constructed 
calibration curves were found to be linear and precise 
for PAR and CZX over the linearity range of 0.5-
40 µg mL-1. The regression equations were also computed 
(Y = 0.0287x + 0.0013, R2 = 0.9998) for CZX and 
(Y = 0.0448x + 0.0099, R2 = 0.998) for PAR.
Selectivity
Selectivity was checked by using 6 randomLy 
selected drug-free rats’ plasma, (processed by the protein 
precipitation extraction procedure for CZX or liquid-liquid 
extraction for PAR) which was analyzed to determine the 
extent to which endogenous plasma components may 
contribute to the interference at the retention time of 
analytes and IS. There was no significant interference at 
the retention times of both CZX, PAR or IS from the six 
different batches of drug-free rat plasma used for analysis, 
as shown in Figures 2 and 3.
Carry-over
Carry-over was assessed by injecting blank samples 
after a high concentration sample (30 µg mL-1) of both 
PAR and CZX. Carry over in the blank sample did not 
exceed 20% of the lower limit of quantification and 5% 
for the internal standard.
Accuracy and precision (inter and intra-day)
For the evaluation of precision, the deviation of 
each concentration level from the nominal concentration 
should to be within ±15.0%. Similarly, the mean 
accuracy should not deviate by ± 15.0% of the nominal 
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FIGURE 1 - Chemical structure of (a) paracetamol, (b) chlorzoxazone.
FIGURE 2 - Chromatogram of (a) blank rat’s plasma (b) Rat plasma spiked with paracetamol (30 µg/mL) and caffeine (80 µg/mL).
concentration except for the LLOQ which should 
be within 20% of the nominal value. The results are 
presented in Tables I and II.
Stability
To evaluate the stability of both PAR and CZX under 
different storage conditions, three aliquots of each low and 
high QC samples were stored in a deep freezer at −80 ± 
2 °C for two weeks. After two weeks, the samples were 
processed along with precision and accuracy batches. 
Concentrations obtained were compared with nominal 
concentrations to determine the long-term stability of both 
PAR and CZX in rat plasma.
The short-term stability was determined by 
keeping three aliquots of unprocessed QC samples at 
ambient temperature for 6.0 h. After 6.0 h, the samples 
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TABLE I - The results of Intra- and Inter-day accuracy and precision for the determination of paracetamol in rat plasma
Accuracy and 
Precision QC samples
Concentration  
of PAR (µg/mL)  
in rat plasma
Mean Found 
Concentration  
(µg/mL) of PAR
±SD CV Recovery %
Intraday
LLOQ 0.5 0.473 0.066 13.953 94.600
Low 1.5 1.490 0.099 6.644 99.333
Medium 20 19.950 0.426 2.135 99.750
High 30 28.707 1.398 4.869 95.690
Interday
LLOQ 0.5 0.500 0.049 9.800 100.000
Low 1.5 1.429 0.089 6.228 95.266
Medium 20 18.840 0.722 3.832 94.200
High 30 28.793 0.603 2.094 95.797
FIGURE 3 - Chromatogram of (a) blank rat’s plasma (b) Rat plasma spiked with chlorzoxazone (30 µg/mL) and esomeprazole 
(44 µg/mL).
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were processed, analyzed and compared with nominal 
concentrations. The stability of QC samples was also 
studied after three freeze and thaw cycles. Three aliquots 
of unprocessed QC samples were stored at −80 ± 2°C 
and subjected to three freeze and thaw cycles. After 
the completion of the third cycle, the samples were 
processed, analyzed and the results were compared with 
nominal values and the results represented in Tables III 
and IV.
Pharmacokinetic analysis
Non-compartmental pharmacokinetic analyses were 
performed using Excel (Microsoft, Redmond, WA, USA) 
add-in program, PK solver. The estimated parameters 
included area under the plasma concentration–time curve 
(AUC0-t), area under the plasma time–concentration 
curve from time zero to infinity (AUC0–∞), maximum 
plasma concentration (Cmax) and time to maximum plasma 
TABLE II - The results of intra- and inter-day accuracy and precision for the determination of chlorzoxazone in rat plasma
Accuracy and 
Precision QC samples
Concentration of 
CZX (µg/mL) 
in rat plasma
Mean Found 
Concentration 
(µg/mL) of CZX
±SD CV Recovery %
Intraday
LLOQ 0.5 0.525 0.040 7.619 105.000
Low 1.5 1.560 0.152 9.744 104.000
Medium 20 20.981 1.634 7.869 104.905
High 30 30.765 1.177 3.826 102.550
Interday
LLOQ 0.5 0.538 0.007 1.301 107.600
Low 1.5 1.503 0.114 7.585 100.200
Medium 20 20.620 1.447 7.017 103.100
High 30 31.794 0.272 0.855 105.980
TABLE III - The results of short, long and freeze and thaw Stability of paracetamol in rat plasma
Stability QC Samples
Concentration of 
PAR (µg/mL) 
in rat plasma
Mean Found 
Concentration 
(µg/mL) of PAR
±SD CV Recovery%
Short Term 
Stability
Low 1.5 1.512 0.019 1.257 100.800
High 30 28.793 0.738 2.563 95.977
Long Ter Stability
Low 1.5 1.437 0.085 5.915 95.800
High 30 28.832 1.897 6.579 96.107
Freeze & Thaw 
stability
Low 1.5 1.533 0.080 5.219 102.200
High 30 30.083 2.367 7.868 100 .277
TABLE IV - The results of short, long and freeze and thaw Stability of chlorzoxazone in rat plasma
Stability QC Samples
Concentration of 
CZX (µg/mL) 
in plasma
Mean found 
Concentration 
of CZX (µg/mL) 
in plasma
±SD CV Recovery%
Short term 
Stability
Low 1.5 1.553 0.139 8.950 103.533
High 30 29.251 0.700 2.400 97.503
Long term 
stability
Low 1.5 1.610 0.034 2.112 107.533
High 30 29.354 0.462 1.574 97.847
Freeze & Thaw 
Stability
Low 1.5 1.566 0.138 8.812 104.400
High 30 30.091 0.364 1.209 100.303
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concentration (Tmax), volume of distribution (Vd), clearance 
(cL) and the elimination half-life (t1/2) of both PAR and 
CZX, Figures 4 and 5 represent the chromatograms of the 
drugs in rat plasma after IV administration.
The plasma concentration–time curves after IV 
administration at PAR (25 mg/kg) and CZX (20 mg/ kg) 
with either control or lycopene pretreatment (20mg/kg, ip) 
are shown in Figure 6. 
The pharmacokinetic parameters of PAR and CZX 
indicated that pretreatment of rats with Lycopene at daily 
dosage of 20mg/kg for eight consecutive days resulted 
in a (20.374% & 45.997%, P < 0.05) reduction in the 
total clearance (cL), respectively, compared with the 
control group. Nevertheless, the difference in volume 
of distribution (Vd) was not significant between the two 
groups of CZX, where there was a significant increase 
(1.694 fold) in Vd of PAR compared to the control group. 
The difference in Cmax and Tmax did not reach 
statistical significance in both PAR and CZX, but the 
AUC0-t, AUC0-inf, t1/2 were significantly increased by 
1.245,1.295 and 2.09 folds in PAR and 1.631, 1.914 and 
2.216 folds in CZX (P < 0.05), respectively, following 
pretreatment with Lycopene (P < 0.05).
Statistical analysis
The different parameters (AUC, Cmax, Tmax, Vd, cL 
and t1/2) of both PAR and CZX between control group 
FIGURE 4 - Chromatogram of paracetamol in plasma taken from a rat after IV administration and spiked with caffeine (80 µg/mL).
FIGURE 5 - Chromatogram of chlorzoxazone in plasma taken from a rat after IV administration and spiked with esomeprazole 
(44 µg/mL).
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FIGURE 6 - (a) The concentration–time profile of paracetamol (25 mg/kg, IV) after treatment with water (control) or lycopene 
(20 mg/kg, ip) in rats (b) The concentration–time profile of chlorzoxazone (20 mg/kg, IV) after treatment with saline (control) or 
lycopene (20 mg/kg, ip) in rats.
TABLE V - Statistical analysis of the results obtained by comparing the control group and lycopene group for the determination of 
pharmacokinetics parameters of paracetamol (25mg/kg) using student’s t-test
Parameter Lycopene Control P cal
Cmax (μg/mL) 23.044±2.254 23.224± 3.032 0.905
t1/2 (h)* 1.327 ±0.355 0.635±0.118 0 .001
Vd (mg/kg)/(μg/mL)* 1.936± 0.701 1.143± 0.242 0.026
cL (mg/kg)/(μg/mL)/h* 1.0001± 0.141 1.256± 0.178 0.020
AUC0-t (μg/mL*h)* 24.62± 3.032 19.773±3.227 0.038
AUC 0-inf (μg/mL*h)* 26.102±3.720 20.150±3.023 0.015
* Significant difference between two groups
TABLE VI - Statistical analysis of the results obtained by comparing the control group and lycopene group for the determination 
of pharmacokinetics parameters of chlorozoxazone (20mg/kg) using student’s t-test
Parameter Lycopene Control P cal
Cmax (μg/mL) 5.264±0.725 5.298±0.424 .9230
t1/2 (h)* 2.988±1.0498 1.348±0.112 .0030
Vd (mg/kg)/(μg/mL) 4.260±0.725 3.834±0.926 .3460
cL (mg/kg)/(μg/mL)/h* 1.059±0.256 1.961±0.352 0.000
AUC0-t (μg/mL*h)* 14.915±1.519 9.143±2.360 0.001
AUC 0-inf (μg/mL*h)* 20.020±5.758 10.460±1.749 .0030
* Significant difference between two groups
and lycopene group were compared. All statistics were 
calculated using IBM SPSS Statistics, Version 22, 
Copyright IBM Corporation and others 1989, 2013. The 
significance of difference between groups was analyzed 
by student’s t-test. Differences were considered significant 
when P < 0.05. The results are represented in Tables V 
and VI.
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DISCUSSION
To determine the affecting dose of lycopene, many 
preliminary trials were carried out. Lycopene (10 mg/kg) 
was given IP to rats for six consecutive days followed by 
IV administration of PAR (25 mg/kg) or CZX (20mg/kg). 
Blood samples were collected from each group at different 
time intervals (0 - 6 h). The results of this experiment were 
compared to that carried out using lycopene (20 mg/kg). 
Control group was carried out for each drug by pretreating 
with the vehicle instead of lycopene. Both experiments 
showed an increase in AUC 0-t, AUC0-inf and a decrease in 
cL of both PAR and CZX when pretreated with lycopene 
but this effect was more significant in the rats pretreated 
with (20 mg/kg) IP lycopene dose. 
This experiment was repeated but with pretreating 
the rats with lycopene 20 mg/kg for eight consecutive days 
instead of six then PAR or CZX was IV administered. This 
showed that the effect of lycopene was more significant 
when the duration of lycopene administration was 
increased.
A herbal or food drug interaction occurs when 
a particular food alters an enzyme activity leading to 
changes in drug metabolism by this enzyme (Saxena et 
al., 2008; Schmidt, Dalhoff, 2002).
Recent study showed the inhibitory effect of tomato 
juice on the metabolism of some substrates of CYP3A4 
such as nifedipine, testosterone and midazolam due to 
the inhibitor effect of lycopene and other flavonoids on 
CYP3A4 (Sunaga et al., 2012). But this work showed 
the inhibitory effect of lycopene on pharmacokinetic 
of paracetamol and chlorzoxazone, which is mainly 
metabolized by CYP2E, due to the inhibitory effect of 
lycopene on CYP2E1.
There are three main metabolic pathways for PAR 
leading to the formation of toxic or non-toxic products and 
eventually excreted in urine (Veronese, McLean, 1991). 
In the third pathway, however, the intermediate product 
N-acetyl-p-benzoquinone imine (NAPQI) is toxic. NAPQI 
is primarily responsible for the toxic effects of PAR. 
Production of NAPQI is due primarily to two cytochrome 
P450 enzymes: CYP2E1 and CYP3A4 (Foye, Lemke, 
Williams, 2008).
On the other hand, CZX is metabolized to OH-CZX 
by the hepatic microsomal cytochrome P450: CYP2E1 in 
humans (Lucas et al., 1995) and rats (Rockich, Blouin, 
1999).
According to experimental results, it can be deduced 
that pretreatment of rats with lycopene in a dose of 20 
mg/kg lead to an increase in the AUC and a decrease in 
cL of both PAR and CZX and this could be a result of 
inhibiting CYP2E1. Because both PAR and CZX have 
low to intermediate hepatic extraction ratio ((Coleman, 
2006; Mehvar, Vuppugalla, 2006), therefore, their hepatic 
clearance depends mainly on the intrinsic clearance (cLint) 
((Bryant, Knights, 2014; Davies, Morris, 1993; Lin, Lu, 
1997). So, according to equation (1), AUC increases when 
clearance (or intrinsic clearance in case of low clearance 
drugs) decreases (Lin, Lu, 1997):
 AUCtotal= dose/cL=dose/fP. Clint  (1)
When the rats were pretreated with Lycopene, the 
intrinsic and hepatic clearances decreased and AUC0-t, 
AUC0-inf of both PAR and CZX increased, whereas 
Lycopene had no significant effect on Cmax as both were 
administered intravenously.
The elimination half-life t1/2 increased when the 
volume of distribution increased, and the total clearance 
decreased (Lin, Lu, 1997) as shown in Equation (2), and 
this was consistent with the experimental results that 
showed an increase of the elimination half-life of both 
PAR and CZX more than 2 folds:
 t1/2 =0.693×Vd/Cl (2)
Using FDA rodent-human dose conversion based 
on 60 kg average human weight (Nair, Jacob, 2016), 
should consume 193 mg of lycopene per day (20*60/6.2 
= 193 mg) to show the difference of the pharmacokinetic 
parameters for the studied drugs. 6.2 is the ratio that 
compares the body surface area of rats with humans.
CONCLUSION
In conclusion, the pharmacokinetic behavior of 
paracetamol and chlorzoxazone was remarkably changed 
in rats after intra-peritoneal administration of lycopene 
(20mg/kg), and thus a human being should consume 193 
mg of lycopene to show the difference of pharmacokinetic 
parameters for the studied drugs. Hence, it could be 
presumed that the increase of AUC and the decrease 
of cL might be due to the inhibitory effect of lycopene 
on CYP2E1, the main enzyme in the metabolism of 
paracetamol and chlorzoxazone. The results of our 
research might contribute to guide future clinical studies.
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